Court Overseeing Federal Xarelto Lawsuits Addresses Bellwether Trial Selection in New Case Management Order

Share Article

Bernstein Liebhard LLP is representing Xarelto lawsuit plaintiffs in U.S. courts, and notes that the outcome of bellwether trials may provide insight into how juries could rule in similar cases involving the blood thinner.

Free Case Review
These trials may provide important insight into how juries will decide other Xarelto lawsuits that put forth similar allegations of fact,

The court overseeing hundreds of federal Xarelto lawsuits ( has issued a new Case Management Order that addresses, among other things, the selection of cases for future bellwether trials. The Order, which was issued on May 4th in the U.S. District Court, Eastern District of Louisiana, directs the parties to meet and confer before June 15th to established procedures for the selection of 40 to 60 cases for specific discovery, as well as the selection of bellwether trial candidates from that initial discovery pool. A proposed Case Management Order detailing these procedures is to be submitted to the Court by June 30, 2015. (In Re: Xarelto Products Liability Litigation, No. 2592)

“Our Firm is representing a number of federal Xarelto lawsuit plaintiffs, and we are pleased that the multidistrict litigation is preparing for bellwether trials. These trials may provide important insight into how juries will decide other Xarelto lawsuits that put forth similar allegations of fact,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered a life-threatening internal bleeding episode, a stroke, deep vein thrombosis or pulmonary embolism due to their use of this blood thinner.

Xarelto Litigations
Xarelto is a new-generation anticoagulant that was initially approved by the U.S. Food & Drug Administration in 2011, and is now indicated for prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. A black box warning on the Xarelto label includes information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*

Court documents indicate that more than 400 Xarelto lawsuits have been filed in the multidistrict litigation underway in Louisiana, all of which allege that the drug’s manufacturers failed to provide adequate warnings regarding its association with serious side effects, including internal bleeding, strokes, deep vein thrombosis and pulmonary embolism. More than 200 similar complaints have been filed in a mass tort program underway in Pennsylvania’s Philadelphia Court of Common Pleas. (In Re: Xarelto Litigation, Case ID 150102349)

According to court records, the plaintiffs named in these cases all allege that Xarelto was misleadingly marketed as a superior alternative to warfarin, and point out that hemorrhaging caused by this older blood thinner can be stopped via the administration of vitamin K . The complaints note that there currently exists no approved antidote to reverse Xarelto bleeding.

Individuals who allegedly experienced internal bleeding and other complications due to Xarelto may be entitled to compensation for medical bills and other damages related to their injuries. Learn more about filng a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.

*, FDA, March 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website